ALFA Filings
Every announcement, straight from the exchange
Every Emcure Pharmaceuticals earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure's Q1 FY27 results show strong performance driven by international markets and HIV (ARV) business, despite a transitional period in domestic operations following organizational restructuring and the acquisition of Sanofi and Roche portfolios.
Emcure reported Q1 FY27 revenue growth of 22.8% YoY with PAT margins expanding 110 bps. Growth was driven by a 34.2% surge in International Business (58% of total revenue).
Emcure surpassed $1 billion in revenue in FY26, growing 16.6% YoY with 41% adjusted PAT growth, driven by strong international performance and domestic expansion.
Emcure surpassed $1B revenue in FY26, driven by strong international growth and high-end niche launches despite a temporary restructuring-led slowdown in their Zuventus portfolio.
Emcure crossed $1Bn revenue milestone in FY26, delivering 16.6% growth and margin expansion. Focus remains on scaling international markets and strategic domestic partnerships (Novo Nordisk, Sanofi, Roche).